Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

768

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer
Metastatic Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma
Colorectal Cancer

Interventions

DRUG: Zongertinib
DRUG: Trastuzumab deruxtecan
DRUG: Trastuzumab emtansine
DRUG: Trastuzumab
DRUG: Capecitabine
DRUG: mFOLFOX6
DRUG: zanidatamab

Sponsor

Boehringer Ingelheim